Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.

Gbolahan O, Hashemi-Sadraei N, O'Neil B.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):644-648. doi: 10.6004/jnccn.2019.7304.

PMID:
31200359
2.

Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.

Mou H, Yu L, Liao Q, Hou X, Wu Y, Cui Q, Yan N, Ma R, Wang L, Yao M, Wang K.

BMC Cancer. 2018 Nov 12;18(1):1105. doi: 10.1186/s12885-018-5021-2.

3.
4.

Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies.

Katz H, Biglow L, Alsharedi M.

J Gastrointest Cancer. 2019 Apr 27. doi: 10.1007/s12029-019-00243-8. [Epub ahead of print] Review.

PMID:
31028537
5.
6.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L.

N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.

7.

Emerging molecular therapeutic targets for cholangiocarcinoma.

Rizvi S, Gores GJ.

J Hepatol. 2017 Sep;67(3):632-644. doi: 10.1016/j.jhep.2017.03.026. Epub 2017 Apr 5. Review.

9.

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.

Zhao P, Li L, Jiang X, Li Q.

J Hematol Oncol. 2019 May 31;12(1):54. doi: 10.1186/s13045-019-0738-1. Review.

10.

Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.

Kriegsmann M, Roessler S, Kriegsmann K, Renner M, Longuespée R, Albrecht T, Loeffler M, Singer S, Mehrabi A, Vogel MN, Pathil A, Köhler B, Springfeld C, Rupp C, Weiss KH, Goeppert B.

BMC Cancer. 2019 Jan 15;19(1):72. doi: 10.1186/s12885-018-5254-0.

11.

Therapeutic options for intrahepatic cholangiocarcinoma.

Bupathi M, Ahn DH, Bekaii-Saab T.

Hepatobiliary Surg Nutr. 2017 Apr;6(2):91-100. doi: 10.21037/hbsn.2016.12.12. Review.

12.

Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.

Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM.

J Hepatol. 2017 May;66(5):952-961. doi: 10.1016/j.jhep.2017.01.010. Epub 2017 Jan 23.

13.

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.

Bhangoo MS, Boasberg P, Mehta P, Elvin JA, Ali SM, Wu W, Klempner SJ.

Oncologist. 2018 May;23(5):518-523. doi: 10.1634/theoncologist.2017-0342. Epub 2018 Jan 31.

14.

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.

Li H, Ma W, Yoneda KY, Moore EH, Zhang Y, Pu LL, Frampton GM, Molmen M, Stephens PJ, Li T.

J Hematol Oncol. 2017 Feb 28;10(1):64. doi: 10.1186/s13045-017-0433-z.

15.

Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.

Chism DD.

J Natl Compr Canc Netw. 2017 Oct;15(10):1277-1284. doi: 10.6004/jnccn.2017.7036. Review.

PMID:
28982752
16.

Future directions in the treatment of cholangiocarcinoma.

Zhu AX.

Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):355-61. doi: 10.1016/j.bpg.2015.02.010. Epub 2015 Feb 19. Review.

PMID:
25966434
17.

Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.

Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Sun W.

Clin Colorectal Cancer. 2019 Jun;18(2):81-90. doi: 10.1016/j.clcc.2019.02.005. Epub 2019 Feb 27. Review.

PMID:
30905548
18.

Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.

Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001974. doi: 10.1101/mcs.a001974. Print 2017 Sep.

19.

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

Farina MS, Lundgren KT, Bellmunt J.

Drugs. 2017 Jul;77(10):1077-1089. doi: 10.1007/s40265-017-0748-7. Review.

PMID:
28493171
20.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

Supplemental Content

Support Center